Sponsor content
345 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Wainua (eplontersen) has been approved for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
-
Prescription medicine decision summaryZoladex is approved for the management of oestrogen-receptor (ER)-positive early and advanced breast cancer in pre- and peri- menopausal women. Zoladex contains the active ingredient goserelin.
-
Australian Public Assessment Report (AusPAR)Zoladex (goserelin) has been approved for the management of oestrogen-receptor positive early and advanced breast cancer in pre- and peri-menopausal women.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BREZTRI AEROSPHERE 160/14.4/5 budesonide 160 mcg/glycopyrronium 14.4 mcg/formoterol fumarate dihydrate 5 mcg pMDI (DFP-EvoCap).
-
-
Prescription medicine registrationActive ingredients: budesonide, formoterol fumarate dihydrate, glycopyrronium bromide.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WAINUA eplontersen (as sodium) 45 mg/0.8 mL solution for injection pre-filled pen.
-
-
Prescription medicine decision summaryWainua (eplontersen) is approved for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adults with stage 1 or 2 polyneuropathy.